Leukemia, Myeloid, Acute
Conditions
Keywords
Leukemia, Acute Myeloid Leukemia, AML, Hematopoietic stem cell transplant, HCT, CD33, Allogeneic, CAR T, CAR-T, Chimeric Antigen Receptor T Cell, CAR T Cells, CAR-T Cells, Immunotherapy
Brief summary
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
Detailed description
CD33 is a preferential target for AML CAR T cell therapy due to its surface expression on the majority (\>80%) of AML blasts and due to the extensive prior clinical experience demonstrating safety and efficacy of targeting CD33 with Mylotarg (gemtuzumab ozogamicin). VCAR33 is being developed as a potential new treatment for patients with relapsed/refractory (R/R) AML after alloHCT. In this Phase 1/2 trial, the safety and efficacy of lentiviral-transduced CD33-directed CAR T cells (VCAR33) generated from the patient's prior allogeneic stem cell donor will be tested. It is hypothesized that CAR T cell production from healthy donors will not only eliminate delays in production due to lymphopenia but also reduce concerns for suboptimal T cell function from exposure to systemic immunosuppression or chemotherapeutic agents. Approximately 24 eligible patients with R/R AML after alloHCT will be enrolled in one of two separate arms based on disease burden (morphologic disease versus measurable residual disease (MRD ) positive). The maximum tolerated dose of VCAR33 will be determined using a 3+3 trial design within each arm. Dose escalation can only occur after a minimum of 3 patients have completed the dose-limiting toxicity (DLT) observation period.
Interventions
BIOLOGICALVCAR33
Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy
Sponsors
Vor Biopharma
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients aged ≥18 years 2. Patients must have CD33+ AML in relapse or refractory after alloHCT 3. Patients must be a recipient of an 8/8 (A, B, C, DRB1) HLA-matched related or unrelated donor alloHCT. Patients previously transplanted with VOR33 in the VBP101 study who have R/R AML may also be considered. 4. Disease status at the time of enrollment: 1. Arm A/Morphologic disease: Defined as ≥ 5% blasts (bone marrow) post-HCT 2. Arm B/MRD positive: \< 5% blasts (bone marrow) with minimal residual disease of at least 0.1% CD33+ leukemia cells by flow cytometry 5. Performance status: ECOG 0 or 1 6. Patient must have adequate organ function as defined by: 1. Cardiac: Left ventricular ejection fraction (LVEF) ≥ 45% or fractional shortening ≥ 28% 2. Pulmonary: Baseline oxygen saturation \> 92% on room air at rest 3. Hepatic: Total bilirubin \< 3x institutional upper limit of normal (ULN) (except in case of patients with documented Gilbert's disease \< 5x ULN) and aspartate aminotransferase (AST/SGOT)/alanine aminotransferase (ALT/SGPT) \< 5x institutional ULN 4. Renal: Serum creatinine must be ≤ 1.2x institutional ULN or creatinine clearance ≥ 60 mL/min for patients with creatinine levels above institutional normal 7. Original alloHCT donor is available and willing to undergo apheresis
Exclusion criteria
1. Patients who have undergone more than one alloHCT 2. Patients who have undergone alloHCT with a mismatched unrelated donor, haploidentical donor, or with umbilical cord blood as the stem cell source 3. Patients who will be less than 100 days post-alloHCT at the time of VCAR33 infusion. 4. Patients with any history of Grade III or IV acute GVHD or severe chronic GVHD unless approved by the Sponsor Medical Monitor 5. Patients with evidence of ongoing active acute or chronic GVHD and are taking systemic immunosuppressive agents (\> 10 mg daily of prednisone equivalent or other GVHD-directed treatment, including extracorporeal photopheresis). Patients with Grade 1 acute GVHD limited to the skin or mild chronic GVHD limited to the eyes, mouth, or skin controlled with only topical therapy are eligible. 6. Patients with active CNS disease. A lumbar puncture is not required to exclude CNS disease in the absence of clinical signs or symptoms suggesting CNS disease. 7. Patients with the following prior therapy: 1. DLI within 28 days prior to enrollment 2. Prior treatment with any CAR T cell therapy product 8. Patients with active or uncontrolled viral, bacterial, or fungal infection 9. Patients with a history of a human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or C infection 10. Patients with a history of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, or breast) unless disease free for at least 3 years after the last definitive therapy 11. Female patients of childbearing potential who are pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of dose-limiting toxicities | Day 28 |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of GVHD related to VCAR33 | Up to 24 months |
| Percentage of patients who achieve response | Up to 24 months |
| Overall survival post-VCAR33 infusion | Up to 24 months |
| Progression-free survival post-VCAR33 infusion | Up to 24 months |
Countries
United States
Outcome results
None listed